459 related articles for article (PubMed ID: 27752787)
1. Multi-institutional phase II study on the feasibility of liver resection following preoperative mFOLFOX6 therapy for resectable liver metastases from colorectal cancers.
Nagayama S; Hasegawa S; Hida K; Kawada K; Hatano E; Nakamura K; Seo S; Taura K; Yasuchika K; Matsuo T; Zaima M; Kanazawa A; Terajima H; Tada M; Adachi Y; Nishitai R; Manaka D; Yoshimura T; Doi K; Horimatsu T; Mitsuyoshi A; Yoshimura K; Niimi M; Matsumoto S; Sakai Y; Uemoto S
Int J Clin Oncol; 2017 Apr; 22(2):316-323. PubMed ID: 27752787
[TBL] [Abstract][Full Text] [Related]
2. Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K-ras status for unresectable colorectal liver metastasis (BECK study).
Hatano E; Okuno M; Nakamura K; Ishii T; Seo S; Taura K; Yasuchika K; Yazawa T; Zaima M; Kanazawa A; Terajima H; Kaihara S; Adachi Y; Inoue N; Furumoto K; Manaka D; Tokka A; Furuyama H; Doi K; Hirose T; Horimatsu T; Hasegawa S; Matsumoto S; Sakai Y; Uemoto S
J Hepatobiliary Pancreat Sci; 2015 Aug; 22(8):634-45. PubMed ID: 25926024
[TBL] [Abstract][Full Text] [Related]
3. Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial - PACHA-01 (NCT02494973).
Goéré D; Pignon JP; Gelli M; Elias D; Benhaim L; Deschamps F; Caramella C; Boige V; Ducreux M; de Baere T; Malka D
BMC Cancer; 2018 Aug; 18(1):787. PubMed ID: 30081865
[TBL] [Abstract][Full Text] [Related]
4. mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808): a multicenter phase II trial comprising the final analysis for survival.
Yasuno M; Uetake H; Ishiguro M; Mizunuma N; Komori T; Miyata G; Shiomi A; Kagimura T; Sugihara K
Int J Clin Oncol; 2019 May; 24(5):516-525. PubMed ID: 30612267
[TBL] [Abstract][Full Text] [Related]
5. A multicenter phase II trial of mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808).
Uetake H; Yasuno M; Ishiguro M; Kameoka S; Shimada Y; Takahashi K; Watanabe T; Muro K; Baba H; Yamamoto J; Mizunuma N; Tamagawa H; Mochizuki I; Kinugasa Y; Kikuchi T; Sugihara K
Ann Surg Oncol; 2015 Mar; 22(3):908-15. PubMed ID: 25465375
[TBL] [Abstract][Full Text] [Related]
6. Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study.
Gibbs P; Gebski V; Van Buskirk M; Thurston K; Cade DN; Van Hazel GA;
BMC Cancer; 2014 Dec; 14():897. PubMed ID: 25487708
[TBL] [Abstract][Full Text] [Related]
7. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival.
Adam R; Delvart V; Pascal G; Valeanu A; Castaing D; Azoulay D; Giacchetti S; Paule B; Kunstlinger F; Ghémard O; Levi F; Bismuth H
Ann Surg; 2004 Oct; 240(4):644-57; discussion 657-8. PubMed ID: 15383792
[TBL] [Abstract][Full Text] [Related]
8. Multicenter phase II study of modified FOLFOX6 as neoadjuvant chemotherapy for patients with unresectable liver-only metastases from colorectal cancer in Japan: ROOF study.
Takahashi T; Shibata Y; Tojima Y; Tsuboi K; Sakamoto E; Kunieda K; Matsuoka H; Suzumura K; Sato M; Naganuma T; Sakamoto J; Morita S; Kondo K
Int J Clin Oncol; 2013 Apr; 18(2):335-42. PubMed ID: 22383023
[TBL] [Abstract][Full Text] [Related]
9. Liver resectability of advanced liver-limited colorectal liver metastases following mFOLFOX6 with bevacizumab (KSCC0802 Study).
Beppu T; Emi Y; Tokunaga S; Oki E; Shirabe K; Ueno S; Kuramoto M; Kabashima A; Takahashi I; Samura H; Eguchi S; Akagi Y; Natsugoe S; Ogata Y; Kakeji Y; Baba H; Maehara Y;
Anticancer Res; 2014 Nov; 34(11):6655-62. PubMed ID: 25368271
[TBL] [Abstract][Full Text] [Related]
10. [HEMIHEPATECTOMY FOR RESECTABLE HEPATIC METASTASIS FROM COLORECTAL CANCER WITH POOR PROGNOSIS].
Patyutko YI; Kotelnikov AG; Mamontov KG; Podluzhny DV; Ponomarenko AA
Vopr Onkol; 2015; 61(3):439-47. PubMed ID: 26242159
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma.
Bathe OF; Dowden S; Sutherland F; Dixon E; Butts C; Bigam D; Walley B; Ruether D; Ernst S
BMC Cancer; 2004 Jul; 4():32. PubMed ID: 15245580
[TBL] [Abstract][Full Text] [Related]
12. [Preoperative chemotherapy in the surgical treatment of colorectal liver metastases].
Dede K; Láng I; Pörneczi B; Mester G; Fekete A; Kőszegi G; Mersich T; Besznyák I; Bursics A
Magy Seb; 2013 Dec; 66(6):325-30. PubMed ID: 24333977
[TBL] [Abstract][Full Text] [Related]
13. Prospective pilot study of neoadjuvant chemotherapy with 5-fluorouracil, folinic acid and oxaliplatin in resectable liver metastases of colorectal cancer. Analysis of 42 neoadjuvant chemotherapies.
Lorenz M; Staib-Sebler E; Gog C; Proschek D; Jauch KW; Ridwelski K; Hohenberger W; Gassel HJ; Lehmann U; Vestweber KH; Padberg W; Zamzow K; Müller HH
Zentralbl Chir; 2003 Feb; 128(2):87-94. PubMed ID: 12632273
[TBL] [Abstract][Full Text] [Related]
14. FOLFOX enables high resectability and excellent prognosis for initially unresectable colorectal liver metastases.
Beppu T; Hayashi N; Masuda T; Komori H; Horino K; Hayashi H; Okabe H; Baba Y; Kinoshita K; Akira C; Watanebe M; Takamori H; Baba H
Anticancer Res; 2010 Mar; 30(3):1015-20. PubMed ID: 20393029
[TBL] [Abstract][Full Text] [Related]
15. Metabolic response to preoperative chemotherapy predicts prognosis for patients undergoing surgical resection of colorectal cancer metastatic to the liver.
Lau LF; Williams DS; Lee ST; Scott AM; Christophi C; Muralidharan V
Ann Surg Oncol; 2014 Jul; 21(7):2420-8. PubMed ID: 24595797
[TBL] [Abstract][Full Text] [Related]
16. Liver only metastatic disease in patients with metastatic colorectal cancer: impact of surgery and chemotherapy.
Padman S; Padbury R; Beeke C; Karapetis CS; Bishnoi S; Townsend AR; Maddern G; Price TJ
Acta Oncol; 2013 Nov; 52(8):1699-706. PubMed ID: 24102180
[TBL] [Abstract][Full Text] [Related]
17. Histological liver injury and surgical outcome after FOLFOX followed by a hepatectomy for colorectal liver metastases in Japanese patients.
Komori H; Beppu T; Baba Y; Horino K; Imsung C; Masuda T; Hayashi H; Okabe H; Ootao R; Watanabe M; Takamori H; Iyama K; Baba H
Int J Clin Oncol; 2010 Jun; 15(3):263-70. PubMed ID: 20238233
[TBL] [Abstract][Full Text] [Related]
18. The COMET Open-label Phase II Study of Neoadjuvant FOLFOX or XELOX Treatment Combined with Molecular Targeting Monoclonal Antibodies in Patients with Resectable Liver Metastasis of Colorectal Cancer.
Kataoka M; Kanda M; Ishigure K; Matsuoka H; Sato Y; Takahashi T; Tanaka C; Deguchi T; Shibata Y; Sato M; Inagaki H; Matsui T; Kondo A; Takano N; Tanaka H; Sakamoto J; Oba K; Kondo K
Ann Surg Oncol; 2017 Feb; 24(2):546-553. PubMed ID: 27638675
[TBL] [Abstract][Full Text] [Related]
19. [Hepatic resection after neoadjuvant therapy for initially unresectable colorectal liver metastases].
Kaibori M; Iwamoto S; Ishizaki M; Matsui K; Saito T; Yoshioka K; Kwon AH
Gan To Kagaku Ryoho; 2009 Dec; 36(13):2579-82. PubMed ID: 20009458
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment of conversion chemotherapy for initially unresectable synchronous colorectal liver metastasis.
Baba K; Oshita A; Kohyama M; Inoue S; Kuroo Y; Yamaguchi T; Nakamura H; Sugiyama Y; Tazaki T; Sasaki M; Imamura Y; Daimaru Y; Ohdan H; Nakamitsu A
World J Gastroenterol; 2015 Feb; 21(6):1982-8. PubMed ID: 25684967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
